Drug Discovery World

OCTOBER 4, 2023

Biotech company 4SC has announced positive new data for its treatment for patients with advanced-stage cutaneous T-cell lymphoma (CTCL). Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL.

Marketing 130

Marketing Treatment Therapies Disease 130

Drug Discovery World

MARCH 24, 2023

Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. Other patients, some of whom are already in late stages of the disease, are awaiting treatment. The researchers estimate that there are dozens to hundreds of people that could benefit from the effective life-saving treatment.

Disease 130

Disease Treatment Research Licensing 130

Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The combination treatment for this indication was approved by the US Food and Drug Administration in 2021 and gained a positive opinion from the CHMP earlier this year.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

AUGUST 23, 2022

The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. . Poster presented at EHA Annual Meeting, Vienna, Austria June 9 – 12, 2022. Abstract P573.

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

Drug Discovery World

AUGUST 29, 2024

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug.

Regulations 147

Regulations Hospitals Licensing Licensing 147

Drug Discovery World

AUGUST 8, 2023

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.

Small Molecule 246

Small Molecule Drugs Licensing Licensing 246

Drug Discovery World

FEBRUARY 23, 2024

FDA approves first T cell therapy in solid tumours The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. £7M The post This week in drug discovery (19-23 February) appeared first on Drug Discovery World (DDW).

FDA Approval 130

FDA Approval Therapies Licensing Licensing 130

Drug Discovery World

AUGUST 1, 2023

Synthetic biology is increasingly important to drug discovery and development. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

Drug Discovery World

APRIL 17, 2024

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The post Novartis buys Arvinas’ prostate cancer protein degrader for $150m appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Clinical Development Treatment 130

Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Drugs 130

Drugs Licensing Licensing Laboratories 130

Drug Discovery World

FEBRUARY 9, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC). versus 11.5%).

Treatment 130

Treatment Clinical Research International FDA 130

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 48

Licensing Licensing Treatment Virus 48

Drug Discovery World

MARCH 6, 2024

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The technology has been proven in the treatment of other dystrophies, including Duchenne muscular dystrophy, and is quick and cost-effective to develop.

Disease 130

Disease FDA Therapies Drugs 130

Drug Discovery World

JULY 11, 2023

We are confident that the strong collaboration of the experienced teams at Evotec and BMS will make novel innovative treatment options available to patients living with a broad range of neurodegenerative conditions.” Evotec and BMS aim to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Licensing 189

Licensing Licensing Drugs Disease 189

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 130

Drugs DNA Licensing Licensing 130

Drug Discovery World

JULY 28, 2023

The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post This week in drug discovery (24-28 July) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Discovery World

NOVEMBER 25, 2022

Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. Hope for drug that slows neurodegenerative disease . Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice.

FDA Approval 130

FDA Approval FDA Drugs Therapies 130

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

SEPTEMBER 8, 2023

Intelligent OMICS and Janssen enter AI research collaboration AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers.

Drugs 130

Drugs Licensing Licensing Government 130

Drug Discovery World

JANUARY 12, 2023

This license allows us to accelerate a promising drug target towards clinical development,” said Fraser Murray, Chief Executive Officer of Pheno Therapeutics. . The post Pheno Therapeutics buys rights to potential remyelination drug appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Licensing Licensing Drugs 130

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Drug Target Review

SEPTEMBER 7, 2023

The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. Together, TCX-101 and TCX-102 allow BlueSphere to have a broader reach in the high-risk leukaemia treatment space where a high unmet medical need exists. -leukaemia effects and reducing graft-vs.-host

Treatment 98

Treatment Licensing Licensing Disease 98

Drug Discovery World

AUGUST 4, 2023

CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). It occurs in people living with age-related macular degeneration (AMD) and affects approximately eight million people globally.

Licensing 130

Licensing Licensing Drugs Disease 130

Drug Discovery World

JANUARY 3, 2023

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). . The post Janssen seeks European approval for multiple myeloma drug appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Drugs Treatment 130

Drug Discovery World

JANUARY 5, 2023

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology. . The post Collaboration will combine ADC technology and precision therapeutics appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Treatment Drugs 130

Drug Discovery World

MARCH 10, 2023

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

Drug Discovery World

JULY 13, 2023

Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).

Drugs 130

Drugs Pharmaceutical Companies Licensing Licensing 130

Drug Discovery World

JULY 2, 2024

This article will examine the regional focus of the country’s life sciences industry, its infrastructure of bioparks, and how this foundation ensures Switzerland maintains its role as a global leader in drug discovery. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

FEBRUARY 17, 2023

A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments. The post Partners hope to “chart a new era of drug discovery” appeared first on Drug Discovery World (DDW).

Bioinformatics 130

Bioinformatics Licensing Licensing Drugs 130

Drug Discovery World

MARCH 17, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. However, to date, there have been severely limited treatment options for those affected.

Virus 130

Virus Regulations Licensing Licensing 130

Drug Discovery World

FEBRUARY 16, 2024

It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. New treatment options are needed to help the HS community find relief from the burden of this disease.”

Licensing 162

Licensing Licensing Treatment Disease 162

Drug Discovery World

MARCH 7, 2024

The merged pipeline features an antibody-drug conjugate (ADC) toolkit with novel payload and linker technologies. It has potential to be the first approved treatment for HSCT-TMA, a rare complication of stem cell transplantation that has an 80% mortality rate among severe adult and paediatric patients.

Clinical Trials 147

Clinical Trials Licensing Licensing Clinical Development 147

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive and consists of an anti-Claudin 18.2

Licensing 40

Licensing Licensing Small Molecule Drugs 40